Search

Summary What is known and objectives: Intoxication with oral low-dose methotrexate (MTX) is a well-known and frequent problem, which is often discovered accidently. The major reason is error in the frequency of dosing, mostly of daily instead of weekly intake. We report a case where the critical error was discovered by the community pharmacist during the routine implementation of the Pharmaceutical Care process SOAP while dispensing a new prescription for the patient. Details of the case: A 78-year-old widow went to her regular community pharmacy to pick up a prescription for oral mucositis. The evaluation of the case by the pharmacist using the SOAP (an acronym for Subjective, Objective, Assessment and Plan) note method revealed the underlying oral low-dose MTX intoxication which led to hospitalization a few days later. The incorrect interpretation of the required dose had arisen from the written instructions for use and led to the erroneous intake of MTX daily (instead of weekly). We interviewed the patient at her home 2 months after discharge. She explained that her continued intake of MTX in spite of manifest adverse effects was because of a profound conviction that she was doing right. Her confidence in physicians remained unchanged after the incident, but she would now refuse to take MTX. What is new and conclusion: The reasons for the intoxication were not discovered accidently but by the routine use of the Pharmaceutical Care process SOAP by the community pharmacist. We describe three main errors that might have been avoided and provide solutions for physicians, pharmacists, manufacturers and patients, to reduce such risks. Our case highlights the dangers of teleconsultation, the crucial role of Pharmaceutical Care provided by community pharmacists and the continued need to supply advice to patients being prescribed low-dose MTX. The fact that a patient has had a previous and successful experience with a similar treatment should not deter health professionals from verifying a patient's understanding via questions and feedback. [ABSTRACT FROM AUTHOR]

Interchangeability between biological medicines and biosimilars, and subsequent substitution by pharmacists represent an important opportunity for costs savings for health care systems. Because biological medicines are complex products, the expert role of the pharmacist to inform patients and support physicians is indispensable. However, regulations on substitution of biosimilars differ around the globe, such that a substitution that is allowed in one country may be forbidden in another. Overall, pharmacists' knowledge of biosimilar medicines is incomplete and hesitancy to engage in substitutions is perceptible. As counter-balancing remedy, continued education about biosimilars is needed among practicing community pharmacists., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 The Authors.)

Objectives: To translate the SWAMECO from German into English; to complete content and face validity with healthcare professionals (HCPs) and with patients from the target population that is, community-dwelling adult patients taking three or more medicines for three or more months., Design: The process followed guidance from Sousa et al and included translation and cross-cultural adaptation, and cognitive testing among selected HCPs and patients. As the SWAMECO questionnaire is a screening instrument, pilot testing was performed in the target population., Setting: Three community pharmacies in and around Cork (Ireland) recruited patients for interviews and pilot testing., Participants: Community-dwelling patients with ≥3 oral medications for ≥3 months, aged ≥18 years., Outcome Measures: Answers to the SWAMECO questionnaire; clarity of each question, each instruction and each response format., Results: Issues related to cultural and conceptual differences were resolved by rewording some items. Ten HCPs and 11 patients completed the questionnaire and gave their feedback and opinions on criteria according to Fitzpatrick et al . Revisions included rewording; deleting of two questions; using of colour to signpost that is, where to skip questions that were not applicable to the participants; and replacement of the A-14 medication adherence scale with three validated items. Of the 66 patients enrolled for pilot testing, eight (12.1%) indicated swallowing difficulties. Difficulties with ingesting foods or liquids correlated with swallowing difficulties (p=0.001). All patients perceived discomfort (mean 6.9 on a Visual Analogue Scale from 0 to 10). Patients with swallowing difficulties were significantly more likely to report modifying their medicines (p=0.004) and having poorer medication adherence (p=0.028) than those who had no swallowing difficulties., Conclusions: The version of the SWAMECO questionnaire in English contains 28 items and is ready for use in adults with polypharmacy., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Response Evaluation Criteria in Solid Tumors (RECIST), including version 1.0 and 1.1, has been universally accepted as the standard response assessment criteria for conventional chemotherapies. Increasing use of immunotherapy led to the need and development of immune-related RECIST. Imaging plays a crucial role in response assessment for solid tumors in guiding patient management as well as in clinical trials. Familiarity to different response criteria will help radiologists to optimally identify, select, and measure tumor lesions per the criteria and assess response to therapy. This article provides a comprehensive review of published RECIST criteria., (Copyright © 2018 Elsevier Inc. All rights reserved.)

Purpose: The case of a patient who experienced bone marrow edema and pain in both feet and a compression fracture of one heel bone after several months of everolimus use is reported., Summary: A 62-year-old woman with a grade 1 metastatic pancreatic neuroendocrine tumor (pNET) developed bilateral lower extremity edema and pain approximately 4 months after initiation of treatment with everolimus, an inhibitor of mammalian (or mechanistic) target of rapamycin (mTOR). The patient was referred for orthopedic evaluation, which resulted in diagnosis of bone marrow edema and a compression fracture of the calcaneus on the basis of magnetic resonance imaging results. The case was discussed with a clinical pharmacist, and after an in-depth analysis to rule out potential alternative causes for the patient's edema and pain, everolimus was discontinued. The patient had a full recovery from the presenting symptoms within 10 days of discontinuation of everolimus. Analysis of this case using the adverse drug reaction probability scale of Naranjo et al. yielded a score of 6, indicating a probable adverse reaction to everolimus. A hypothesized mechanism for everolimus-induced bone pain includes marrow edema and hyperemia from reduced intraosseous perfusion, which have been previously reported in association with mTOR inhibitor use., Conclusion: Bone marrow edema developed and a fracture occurred in a patient taking everolimus for a metastatic pNET, with complete resolution of lower extremity swelling and pain within 2 weeks of everolimus discontinuation., (Copyright © 2018 by the American Society of Health-System Pharmacists, Inc. All rights reserved.)

Optimal communication between physicians and pharmacists is important for patient care. However, pharmacists and doctors do not always seem to understand each other. They have been professionalized differently, and do not always speak the same language. Especially in the areas of prescribing, medication review, and medicine use, there can be differences in views. This contribution clarifies some essential concepts that doctors and pharmacists use. Thus we hope that our commentary contributes to a better understanding of each other's role and the importance of interprofessional cooperation for the benefit of the patient.

A unique approach of automating the integration of monolithic capillary HPLC-based protein separation and on-plate digestion for subsequent MALDI-MS analysis has been developed. All liquid-handling procedures were performed using a robotic module. This automated high-throughput method minimizes the amount of time and extensive labor required for traditional in-solution digestion followed by exhaustive sample cleanup and analysis. Also, precise positioning of the droplet from the capillary HPLC separation onto the MALDI plate allows for preconcentration effects of analytes for improved sensitivity. Proteins from primary esophageal Barrett's adenocarcinoma tissue were prefractionated by chromatofocusing and analyzed successfully by this automated configuration, obtaining rapid protein identifications through PMF and sequencing analyses with high sequence coverage. Additionally, intact protein molecular weight values were obtained as a means to further confirm protein identification and also to identify potential sequence modifications of proteins. This simple and rapid method is a highly versatile and robust approach for the analysis of complex proteomes.

The actual administration of pharmacotherapy is in most cases entirely up to the patient. Correct application can often be only achieved with application aids. They are already part of many preparations: printed blister packages, measures for dosing liquids, applicators for topical use, dosage sprays, and supports for eye drop containers. Special needs can be covered by additional application aids like dosage syringes for child medication, spacers for asthma sprays, devices for splitting or crunching tablets. Filling the medicines in containers better manageable by the patient, in week dispensers or week blisters, may also be crucial to guarantee correct dosing and regimen. Application aids often play a significant part in the success of a therapy. Needed are evidence based criteria for the selection of devices and instructions. Such criteria need to be developed because they are still largely lacking.

Now as in the past, tobacco consumption is a major health problem in Switzerland. Efforts to reduce tobacco consumption include different preventive strategies. Although dispensary pharmacists have increased their efforts in health promotion and prevention in recent years, their role in tobacco prevention has not been documented so far. The "Tobacco Adieu!" campaign to support smoking cessation was introduced in pharmacies as a low threshold offer in Basle in 1996. This paper assesses the process and the effect of this effort. Participating pharmacies were interviewed during the evaluation and all consultations in this area were recorded in questionnaires. Customers requesting counselling from pharmacies during the campaign were also asked to fill in a questionnaire regarding their smoking behaviour and their experiences in the pharmacy. The offer was well accepted by the public: During the four week period, about 2,000 client contacts for smoking cessation took place in the 63 participating pharmacies. Compared to the pre-campaign situation, more intensive counselling took place. Clients who received counselling in the pharmacies generally attested to its good quality. In addition to counselling, further care during the smoking cessation phase was offered to clients who wanted to quit smoking. Follow-up visits were agreed in 76 percent of the cases. The project shows that smokers can be motivated to consider cessation and supported in the process by pharmacists. Therefore, pharmacies can be used as a low threshold offer in this context. Expansion of this programme in public pharmacies seems justified. However, continuing education and a motivated team are the prerequisites for successful counselling of smokers in pharmacies.

For the first time unused drugs have been analyzed in Switzerland. The two non profit organizations MEDI HELP DIRECT in Zurich and Pharmaciens sans Frontières in Neuchâtel collected the unused drugs with the aim to examine the quality and the quantity of the medication returned to the pharmacies. In both cantons about 5000 units have been registered and examined with the respect to shelf-life, contents, requirement of prescription and reimbursement by health companies. Two thirds of the drugs have 50-100% contents left over. Prescribed medicines returned faster to the pharmacies and are less often expired.